Jpmorgan Chase & CO Pro Phase Labs, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,797 shares of PRPH stock, worth $916. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,797
Previous 1,800
0.17%
Holding current value
$916
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding PRPH
# of Institutions
34Shares Held
2.68MCall Options Held
12.3KPut Options Held
0-
Sykon Capital LLC Harrison, NY645KShares$328,8450.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA408KShares$208,2160.0% of portfolio
-
Geode Capital Management, LLC Boston, MA259KShares$132,1220.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL229KShares$117,0210.0% of portfolio
-
Quinn Opportunity Partners LLC Charlottesville, VA218KShares$111,2440.01% of portfolio
About ProPhase Labs, Inc.
- Ticker PRPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 16,024,400
- Market Cap $8.17M
- Description
- ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...